Physician profile
Michael B Loewinger
NPI 1477703007
$2,355.04
in general payments reported to CMS, 2019-2025
32 companies · $766 in 2025
The $766 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $458 · 2020: $209 · 2021: $246 · 2022: $135 · 2023: $290 · 2024: $252 · 2025: $766.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,308.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,307.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $383.95 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $335.95 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $193.73 | 2019-2025 | Xifaxan, Trulance |
| Glaxosmithkline, LLC. | $148.93 | 2022-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Lilly USA, LLC | $125.47 | 2019-2025 | Mounjaro, Kisunla |
| Otsuka America Pharmaceutical, INC. | $101.26 | 2023-2025 | Rexulti, Nuedexta |
| Exact Sciences Corporation | $95.13 | 2023-2025 | Cologuard Collection Kit |
| Ucb, INC. | $90.47 | 2023-2025 | Cimzia, Bimzelx |
| Amgen INC. | $83.50 | 2021-2025 | Otezla, Repatha, Evenity |
| Pfizer INC. | $82.81 | 2019-2023 | |
| Lundbeck LLC | $78.71 | 2020-2025 | Rexulti |
| Scilex Pharmaceuticals INC. | $62.03 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $54.65 | 2021-2025 | Verquvo |
| Digital Diagnostics INC. | $49.33 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $46.07 | 2023-2025 | Farxiga, Airsupra |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $44.30 | 2022 | |
| Abbvie INC. | $41.49 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.75 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $34.82 | 2025 | |
| Sanofi Pasteur INC. | $29.97 | 2020-2023 | |
| Boston Scientific Corporation | $29.75 | 2024 | Emblem Mri S-Icd |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.35 | 2022-2025 | Jardiance |
| Arbor Pharmaceuticals, INC. | $29.01 | 2021 | |
| Xeris Pharmaceuticals, INC. | $27.07 | 2023-2024 | Gvoke Hypopen |
| Seqirus USA INC | $19.00 | 2025 | Fluad, Flucelvax |
| Depuy Synthes Sales INC. | $17.82 | 2019 | |
| Insulet Corporation | $16.35 | 2023 | Omnipod |
| Acorda Therapeutics, INC | $15.00 | 2019 | |
| Amarin Pharma, INC. | $14.98 | 2019 | |
| Biogen, INC. | $13.44 | 2021 | |
| Novartis Pharmaceuticals Corporation | $12.32 | 2020 | |
| Cequr Corporation | $10.63 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Loewinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.